Notably, treatment of metastatic NSCLC has greatly advanced through application of immune checkpoint blockers (ICB) of programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein (CTLA-4) (Chae et al., 2018). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.